Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer
Article
Hart, MC, Schrock, AB, Ou, SHI et al. (2016). Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer
. 9 131-133. 10.1016/j.ctarc.2016.08.010
Hart, MC, Schrock, AB, Ou, SHI et al. (2016). Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer
. 9 131-133. 10.1016/j.ctarc.2016.08.010
Third-generation irreversible epidermal growth factor receptor (EGFR) inhibitors have shown clinical benefit for non-small cell lung cancer (NSCLC) patients with T790M resistance mutations, and one inhibitor, osimertinib, recently received FDA-approval in this population. We present three NSCLC patients with low frequency T790M mutations who initially received false negative results for the presence of EGFR T790M before hybrid-capture based comprehensive genomic profiling positively identified the presence of the mutation in matched tissue biopsies. The course of therapy before identification of T790M and the subsequent treatments and clinical outcomes are described for each patient. Each case demonstrates missed clinical benefit due to false negative testing for EGFR T790M, and highlights the need for sensitive and accurate detection of targetable genomic alterations in order for patients to potentially benefit from matched targeted therapies.
